GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Saturday, May 2, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 15

Author

Pharma Journalist 8769 posts 0 comments

Catalent, S.Biomedics Partner on Parkinson’s Cell Therapy

Feb 19, 2026
Catalent and S.Biomedics have entered into a strategic partnership to advance the development and manufacturing of TED-A9, an investigational allogeneic pluripotent stem cell-derived…
Read More...

Johnson & Johnson Invests $1 Billion in Pennsylvania

Feb 19, 2026
Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Unnatural Products, Novartis Partner on Macrocyclic Therapies

Feb 19, 2026
Unnatural Products, Inc. (UNP), a biotechnology company focused on developing orally delivered macrocyclic peptides for hard-to-drug targets, has entered into a research collaboration…
Read More...

Scribe, Lilly Advance CRISPR Therapies With Milestone

Feb 18, 2026
Scribe Therapeutics, Inc. has achieved a second success milestone in its ongoing collaboration with Eli Lilly and Company, marking further progress in the development of in vivo…
Read More...

Teijin, Aska Partner on Gynecology Drug Discovery

Feb 17, 2026
Teijin Pharma Limited has signed a joint research agreement with Aska Pharmaceutical Co., Ltd. to develop new small-molecule drug candidates for gynecological diseases, marking a…
Read More...

The Toxicology Meeting That’s Different – Made for Biotech and Pharma Leaders

Feb 17, 2026
The Investigative & Preclinical Toxicology Summit (May 12-14 | Boston, MA) is set to redefine toxicology meetings for biotech and pharmaceutical professionals. Unlike traditional…
Read More...

Immunic Raises $400M to Advance MS Drug Plans

Feb 16, 2026
Immunic, Inc. announced it has priced a private placement expected to generate up to $400 million in gross proceeds, funding the company’s shift from a research-focused biotech to a…
Read More...

FDA Rejects Bitopertin Accelerated Approval for Rare Disorder

Feb 16, 2026
Disc Medicine said the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for its New Drug Application seeking approval of bitopertin to treat erythropoietic…
Read More...

PTC Withdraws Translarna FDA Application After Feedback

Feb 16, 2026
PTC Therapeutics has withdrawn its resubmitted New Drug Application for Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy after receiving review feedback from…
Read More...

ArkBio Wins U.S. Clearance for IPF Drug Trial

Feb 13, 2026
China-based biotech developer Shanghai Ark Biopharmaceutical Co., Ltd. has received clearance from the U.S. Food and Drug Administration to begin a U.S. clinical study of its…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.